Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Sapanisertib (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Pharmacokinetics; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 06 Mar 2017 Status changed from suspended to recruiting.